Skip to main content

Advertisement

Table 2 Incremental cost for regional treatment equity

From: Inequalities in pharmacologic treatment of spasticity in Sweden – health economic consequences of closing the treatment gap

Healthcare regionTotal incremental number of BoNT-A treatment sessionsaTotal incremental cost per yearb (EUR 2017)Total incremental number of ITB pumpscTotal incremental cost per yeard (EUR 2017)
Stockholm-Gotl.946542,9992501,033,523
Örebro-Uppsala833656,135201833,023
Western1143222,295176727,773
Southerne137567,799
South Eastern387477,92440164,573
Northerne13577,420
Total34431,976,7738043,326,692
  1. aAssuming highest level reported by the healthcare regions (13.6%) corresponds to optimal level
  2. bBased on the mean procedural cost per patient for EMG-guided injection of botulinum toxin for ICD-codes G811, G821 and G824 (~EUR 574). Source: Cost Per Patient database (2017), Swedish Association of Local Authorities and Regions
  3. cAssuming highest level reported by the healthcare regions (14.1/100,000) corresponds to optimal level
  4. dBased on the total cost for implantation of pump, drug costs and three refills of 30 ml per year
  5. eThese healthcare regions used as reference for treatment equity of BoNT-A treatment and ITB pumps, respectively. Hence no values for incremental number are assigned